PCOS Is Now PMOS: What the Name Change Means for Metabolic Health, and How Peptide Therapy Is Reshaping Treatment

What Is PCOS / PMOS, and Why Are People Suddenly Talking About It?

If you have ever been told “it is just your hormones,” been handed a birth control prescription as the entire solution, or walked out of a doctor’s office feeling dismissed, this article is for you.

PCOS (Polycystic Ovarian Syndrome) is a condition affecting roughly one in eight women worldwide, or more than 170 million people globally. For decades it has been characterized by irregular periods, stubborn weight gain, acne, facial hair, fatigue, and fertility challenges. Women living with it have often been told to eat less, move more, and accept it as a hormonal inconvenience.

That narrative is now changing, in a significant way.

On May 12, 2026, the world’s most prestigious medical journal, The Lancet, published the results of a 14-year global effort involving 56 leading academic, clinical, and patient organizations. The conclusion was unanimous: PCOS is the wrong name. It has been officially renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. And that change carries enormous implications for how this condition is understood, diagnosed, and treated, including the growing role of targeted peptide therapy.

The Name Change That Changes Everything

For decades, a diagnostic trap was built into the very name of this condition. Doctors looked for cysts on an ultrasound. No cysts, no diagnosis, even when a patient was experiencing every single symptom: facial hair, acne, irregular periods, severe fatigue, and weight that would not move regardless of diet or exercise.

The problem is that cysts were never the cause. They were, at best, an occasional side effect.

As the Lancet authors stated, the term PCOS was “inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing.”

The new name, PMOS, deliberately corrects this:

• Polyendocrine recognizes that multiple hormonal systems are involved, including insulin, androgens, thyroid hormones, cortisol, Vitamin D, and neuroendocrine signals, not just estrogen and testosterone.
• Metabolic acknowledges the core role of insulin resistance, blood sugar dysregulation, cardiovascular risk, and metabolic syndrome.
• Ovarian retains the connection to ovulatory dysfunction and reproductive health.

This is not a semantic update. It is a complete reframing of what this condition actually is, and who it affects.

“Renaming this condition is more than semantics. It is about finally recognizing the full reality of what patients experience.” — Melanie Cree, MD, PhD, University of Colorado Anschutz, from the Global Name Change Consortium.

The Real Driver: Insulin Resistance and a Broken Signaling System

Here is the key insight that changes everything from a clinical perspective. PCOS/PMOS is not fundamentally a reproductive disorder. It is a signaling disorder, rooted in how the body processes blood sugar and communicates between cells.

Insulin resistance sits at the center of this. When cells stop responding efficiently to insulin, the body produces more of it to compensate. Chronically elevated insulin then signals the ovaries to produce excess androgens (male hormones). Those androgens disrupt the hypothalamic-pituitary-ovarian axis, leading to irregular cycles, anovulation, and the rest of the hormonal cascade women with PCOS/PMOS know all too well.

This is why lifestyle interventions that improve insulin sensitivity, such as a low-glycemic diet, regular strength training, stress reduction, adequate sleep, and targeted nutritional support, form the non-negotiable foundation of any PMOS management strategy. No peptide protocol, supplement, or medication replaces this work. But for many women, that foundation alone is not enough.

That is where targeted peptide support enters the picture.

Why GLP-1 Signaling Is Central to PMOS, Not Just Weight Loss

GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring peptide produced in the small intestine in response to eating. It signals the pancreas to release insulin in a glucose-dependent manner, reduces appetite, slows gastric emptying, and protects organs including the heart, kidneys, and liver.

Here is what emerging research is revealing: many women with PCOS/PMOS produce significantly lower amounts of GLP-1 naturally. This is not a weight issue. It is a biological signaling deficit that affects how the entire metabolic system functions. GLP-1 receptors exist throughout the body, including the brain, heart, kidneys, liver, and, yes, even the bladder and reproductive organs.

A 2025 review in Current Obesity Reports found that GLP-1-mediated metabolic improvements in PCOS patients extended to reductions in hyperandrogenism and improvements in menstrual regularity, not just weight loss. A separate PMC-published scoping review confirmed that GLP-1 receptor agonists “cause insulin release in a glucose-dependent manner, yielding clinical benefits such as heightened satiety, reduced appetite, and appetite regulation,” while also improving lipid profiles and inflammatory markers in women with PCOS.

Tirzepatide, a dual GLP-1/GIP agonist, adds a second mechanism by also activating GIP (Glucose-dependent Insulinotropic Polypeptide) receptors, offering a more comprehensive metabolic reset. For women with PMOS who present with elevated fasting insulin, dyslipidemia, elevated BMI, or a family history of metabolic disease, this dual mechanism may provide meaningful support beyond what lifestyle changes alone can achieve.

From a functional medicine perspective, GLP-1 receptor agonists are not just “weight loss drugs.” They are systemic signaling compounds that address one of the core biological deficits underlying PMOS.

An important note: dosing matters enormously, and this is where working with a qualified practitioner makes all the difference.

• If BMI is over 25, a weight-loss dosing protocol may be appropriate.
• If BMI is under 25, micro-dosing for metabolic optimization, organ protection, and longevity may be the more relevant approach.

The Liver: The Hormone Processing Plant Nobody Is Talking About

Conventional PMOS treatment often focuses on adding hormones, suppressing androgens, or prescribing birth control. From a functional medicine standpoint, this approach misses a critical upstream player: the liver.

The liver is the primary organ responsible for processing and clearing hormones from the body. When the liver is overburdened, often due to metabolic stress, environmental toxin load, poor gut function, or nutritional deficiencies, hormones are not properly cleared. They recirculate, contributing to estrogen dominance, androgen excess, and the hormonal chaos that drives PMOS symptoms.

This is why Glutathione, often called the “master antioxidant,” deserves serious attention in any PMOS protocol. Glutathione is produced naturally in the liver and is essential for detoxification, reducing oxidative stress, and supporting phase 2 liver metabolism. Research consistently shows that women with PCOS/PMOS tend to have lower levels of endogenous antioxidants, including Glutathione, compared to healthy controls.

Supporting liver drainage with Glutathione is particularly relevant when a patient presents with:

• Persistent skin issues (acne, rashes, dullness)
• Sinus congestion or chronic post-nasal drip
• Irregular or sluggish bowel movements
• Chemical sensitivity or difficulty with detoxification pathways

Glutathione support is not a standalone PMOS treatment. But it is a foundational piece of restoring the body’s ability to process what it is already producing, or being given through peptide support.

MOTS-c: The Mitochondrial Peptide for Energy and Visceral Fat

One of the more exciting areas of metabolic peptide research involves MOTS-c, a small peptide encoded within mitochondrial DNA. Unlike most peptides, which are encoded in nuclear DNA, MOTS-c originates directly from the mitochondria, making it a unique biological messenger for cellular energy and metabolic function.

Published research in Cell Metabolism demonstrated that MOTS-c promotes metabolic homeostasis by activating AMPK (a key cellular energy sensor), improving insulin sensitivity in skeletal muscle, and reducing both diet-induced obesity and visceral fat accumulation in preclinical models. Importantly, MOTS-c appears to preferentially target visceral adipose tissue, the metabolically active fat stored around internal organs, which is strongly associated with insulin resistance, cardiovascular risk, and PMOS progression.

A 2024 systematic review in Diabetology and Metabolic Syndrome confirmed that MOTS-c has “a strong relationship with the expression of inflammation- and metabolism-associated genes and metabolic homeostasis,” with evidence suggesting protective effects against insulin resistance.

For PMOS patients whose primary concern is chronic fatigue, metabolic sluggishness, or stubborn visceral belly fat that does not respond to standard interventions, MOTS-c represents a promising adjunct to explore, under proper clinical supervision.

The Functional Medicine Approach: More Than Peptides

Peptides are tools, not magic. The most effective PMOS outcomes come from a layered strategy that addresses the full metabolic picture. From a functional medicine perspective, that includes:

Diet and Nutrition A low-glycemic, anti-inflammatory diet is foundational. Reducing refined carbohydrates and sugars directly reduces the insulin burden driving PMOS. Increasing dietary fiber supports gut microbiome health, which in turn influences estrogen metabolism through the estrobolome. Adequate protein intake supports lean muscle mass, particularly important when using GLP-1 therapies that can affect body composition.

Strength and Movement Resistance training is one of the most powerful insulin sensitizers known. Regular strength training improves glucose uptake in skeletal muscle, reduces visceral fat, and supports hormonal balance. For PMOS patients with fatigue or low motivation, even 2 to 3 sessions per week of moderate resistance exercise can produce meaningful metabolic changes.

Stress and Cortisol Management Chronic stress elevates cortisol, which directly worsens insulin resistance and contributes to androgen excess. Mindfulness practices, adequate sleep (7 to 9 hours consistently), and addressing HPA axis dysregulation are non-negotiable components of any serious PMOS protocol.

Targeted Nutritional Support Several nutrients show consistent evidence of supporting insulin sensitivity and hormonal balance in PCOS/PMOS, including Inositol (myo-inositol and D-chiro-inositol), Magnesium, Vitamin D, Zinc, and N-acetyl cysteine (NAC). These are not replacements for medical care but they are clinically meaningful additions to a comprehensive plan.

Testing Before Treating One of the most important things a functional medicine evaluation adds to PMOS care is comprehensive testing that goes beyond basic hormone panels. Fasting insulin, HOMA-IR, full thyroid panel, inflammatory markers (hs-CRP), nutrient levels, and organic acids testing can reveal the specific metabolic imbalances driving an individual’s presentation, allowing for truly personalized support rather than a one-size-fits-all protocol.

A Note on the Functional Medicine and Peptide Model

At Atlant Chiropractic, our approach to peptide support is rooted in education, evaluation, and appropriate clinical referral. As a functional medicine practitioner, Dr. Kanevsky’s role is to help patients understand the metabolic landscape, identify patterns through comprehensive evaluation, and connect them with licensed prescribing physicians when peptide therapy is clinically appropriate.

This model fills a real gap in current care. Telehealth platforms offering GLP-1 prescriptions often operate in 10-minute visits with no metabolic context, no evaluation of liver function, stress physiology, or gut health, and no follow-up plan that includes lifestyle and nutritional strategy. Patients deserve better than that.

A proper functional medicine evaluation includes a comprehensive review of lab work, metabolic history, lifestyle factors, and health goals before any peptide protocol is considered. That context is what makes the difference between a short-term intervention and a long-term metabolic transformation.

For patients who are ready to take the next step, I work with EllieMD, a physician-directed telehealth platform built around exactly this kind of individualized care. Rather than offering a generic protocol based on weight alone, EllieMD connects patients with licensed medical providers who review your full health history and design a program around your specific goals and biology.

Their catalog includes GLP-1/GIP compounds, MOTS-c, Glutathione, and a range of other evidence-informed peptide options, with everything prescribed and dispensed directly through licensed physicians. If you are curious whether a peptide-supported approach to PMOS management might be appropriate for you, their process begins with a health assessment and a medical review, before anything is prescribed or dispensed.

Related Reading

Further Resources on Peptides and Metabolic Health at Atlant Chiropractic:

• GLP-1, Weight Loss, and Toxin Release: What You Need to Know
• Functional Medicine at Atlant Chiropractic: The Root-Cause Approach
• Explore All Functional Medicine Articles

Key Takeaways

• PCOS has been officially renamed PMOS (Polyendocrine Metabolic Ovarian Syndrome) in a landmark May 2026 Lancet publication, reflecting 14 years of global collaboration across 56 organizations.
• The new name correctly identifies PMOS as a multi-system metabolic and endocrine disorder, not primarily an ovarian condition, affecting more than 170 million women worldwide.
• Many women with PCOS/PMOS have a measurable biological deficit in GLP-1 signaling, contributing to insulin resistance, androgen excess, and the full hormonal cascade.
• Tirzepatide (a dual GLP-1/GIP agonist) may support metabolic reset, reduce systemic inflammation, and improve hormonal signaling, with dosing approaches differing between weight-loss and longevity micro-dosing categories.
• Glutathione supports liver drainage and antioxidant capacity, both of which are commonly compromised in PMOS and essential for proper hormone metabolism.
• MOTS-c, a mitochondria-derived peptide, shows promise for improving insulin sensitivity, reducing visceral fat, and supporting cellular energy metabolism.
• Foundational lifestyle work, including a low-glycemic diet, resistance training, stress management, sleep optimization, and targeted supplementation, remains the non-negotiable base of any PMOS strategy.
• A comprehensive functional medicine evaluation, rather than symptom-chasing or prescription-first approaches, is the most effective starting point for personalizing PMOS care.

Closing Reflection

The renaming of PCOS to PMOS is not just a medical update. It is an acknowledgment, finally, that millions of women have been navigating a condition that medicine did not fully understand, or bother to accurately name, for decades.

The good news is that the science is catching up. We now understand the metabolic engines driving PMOS with far more precision than before. We have tools, including targeted peptide support, comprehensive functional medicine evaluation, and evidence-informed lifestyle strategies, that can meaningfully address those engines, not just manage the symptoms they produce.

The most important question is not whether a specific peptide is right for you. It is whether you have ever had a clinician sit with you, review your full metabolic picture, and ask: “What is actually driving your symptoms, and what does your biology specifically need to thrive?”

If the answer is no, that conversation is worth having.

Frequently Asked Questions

What is the difference between PCOS and PMOS?

PCOS (Polycystic Ovarian Syndrome) and PMOS (Polyendocrine Metabolic Ovarian Syndrome) refer to the same condition. PMOS is the new official name, adopted in May 2026 following a landmark global consensus study published in The Lancet. The change reflects the understanding that this is a full-body metabolic and endocrine disorder, not primarily a condition defined by ovarian cysts. Many women with PMOS do not have cysts at all. The new name highlights the roles of insulin resistance, multiple hormone systems, and metabolic dysfunction in driving the condition.

Can you have PMOS without ovarian cysts?

Yes. This is one of the most important clarifications the new name provides. A significant number of women with PMOS never develop ovarian cysts, which under the old diagnostic model led to delayed or missed diagnoses. PMOS is diagnosed based on a combination of hormonal, metabolic, and clinical criteria, not solely on ultrasound findings.

What peptides are used for PCOS / PMOS?

The peptides most studied and discussed in the context of PMOS metabolic management include GLP-1 receptor agonists (such as Semaglutide), dual GLP-1/GIP agonists (such as Tirzepatide), and emerging mitochondrial peptides such as MOTS-c. Glutathione is also used as a supportive antioxidant and liver drainage peptide/compound in functional medicine PMOS protocols. All peptide therapies should be evaluated and prescribed by a licensed physician following comprehensive metabolic assessment.

Is Tirzepatide (Mounjaro/Zepbound) approved for PCOS or PMOS?

As of 2026, Tirzepatide is FDA-approved for Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Its use in PMOS is considered off-label, supported by a growing body of clinical data on GLP-1 and dual agonist therapies in women with insulin resistance and PCOS/PMOS. Any prescribing decision should involve a licensed physician who can evaluate your individual clinical picture.

What is MOTS-c and how does it relate to PMOS?

MOTS-c is a peptide encoded within mitochondrial DNA. Research has shown it promotes insulin sensitivity, activates AMPK (a cellular energy regulator), and reduces visceral fat in preclinical models. Because PMOS involves significant mitochondrial and metabolic dysfunction, MOTS-c is an area of active clinical interest. Human clinical data is still developing, making medical supervision essential for any use.

Can PMOS be managed without medication or peptides?

Lifestyle interventions, including a low-glycemic diet, regular resistance training, stress management, sleep optimization, and targeted nutritional support, are the first-line and most foundational strategies for PMOS management. Many individuals see meaningful improvement through lifestyle alone. Peptide therapies and medications are considered when lifestyle interventions are insufficient, or when the metabolic deficit is significant enough that biological support is clinically warranted.

How does functional medicine approach PMOS differently from conventional medicine?

Conventional PMOS care typically focuses on symptom management, such as prescribing oral contraceptives for cycle regulation or androgen-blocking medications. Functional medicine approaches PMOS by identifying the root metabolic drivers, including insulin resistance, liver function, gut health, nutrient deficiencies, thyroid status, and HPA axis dysregulation, and building a personalized protocol that addresses those drivers. Peptide support, when appropriate, is integrated into that broader plan rather than prescribed as a standalone solution.

How do I know if peptide therapy is right for my PMOS?

A comprehensive metabolic evaluation is the appropriate starting point. This typically includes fasting insulin and glucose, HOMA-IR (insulin resistance index), full thyroid panel, sex hormone panel, inflammatory markers (hs-CRP), Vitamin D, and often additional functional testing. This level of evaluation, rather than a brief telehealth visit, provides the clinical context needed to determine whether and which peptide support is appropriate for your unique biology.

References

1. Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026. DOI: 10.1016/S0140-6736(26)00717-8. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
2. Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome. PubMed. 2026. PMID: 42119588. https://pubmed.ncbi.nlm.nih.gov/42119588/
3. Hudanich K, et al. The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review. PMC / Cureus. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12551431/
4. Filippatos TD, et al. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. PMC. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10532286/
5. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. https://www.sciencedirect.com/science/article/pii/S1550413115000613
6. Zhou Q, Yin S, Lei X, et al. The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis. Diabetology and Metabolic Syndrome. 2024;16:200. https://link.springer.com/article/10.1186/s13098-024-01405-w
7. Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care. Press Release. 2026. https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change
8. University of Colorado Anschutz Medical Campus. Global Experts, Including CU Anschutz Researcher, Rename Polycystic Ovary Syndrome (PCOS). 2026. https://news.cuanschutz.edu/news-stories/pcos-new-name

FDA Disclaimer: The statements made in this article have not been evaluated by the Food and Drug Administration. The information provided is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Peptide therapies discussed in this article require evaluation, prescription, and supervision by a licensed physician. Always consult a qualified healthcare provider before beginning any new supplement, peptide, or medical protocol. Dr. Aleksander Kanevsky, DC, CFMP is a Doctor of Chiropractic and Certified Functional Medicine Practitioner. He does not prescribe medications or peptides. His role is patient education, comprehensive functional medicine evaluation, and clinical referral to licensed prescribing physicians where appropriate.

Author: Aleksander Kanevsky, DC, CFMP